PDCD1 and melanoma: While anti-CSF-1R treatments demonstrated limited efficacy alone (Ries et al., 2015), anti-CSF1R treatment in combination with anti-PD-1 therapy significantly decreased M2 TAMs while increasing the number of CD4+ and CD8+ TILs in murine models of melanoma (Neubert et al., 2018).